Key Highlights

  • Teva shares are trading down 2.95% at $40.85, against a previous close of $42.09.
  • Teva will discontinue the Phase 2 TOPAS-MSA study after an interim futility analysis.
  • No safety concerns were identified, and the broader emrusolmin program is not yet decided.

Teva (NYSE:TEVA) shares are trading down 2.95% at $40.85, against a previous close of $42.09, after the company said it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin in multiple system atrophy. The shares have pulled back from a 52-week high near $42.59, and Volume is running above 5 million shares.

Teva is headquartered in Tel Aviv and was founded in 1901. It pairs one of the world's largest generics businesses with a growing portfolio of innovative and biopharmaceutical medicines, and its specialty focus is on central nervous system, respiratory and oncology therapies, including Austedo, Ajovy, Uzedy and Copaxone. In 2025 the company reported revenues of about $17.3 billion, up 4%, and its key innovative brands passed $3 billion in sales as it continues its Pivot to Growth strategy.

Why the Study Is Stopping

The decision follows a recommendation from the independent data monitoring committee, based on a prespecified interim futility analysis. The analysis met the predefined futility criterion, which indicates a low probability that the study would meet its primary efficacy endpoint if it continued. Teva stressed that this was an interim predictive assessment and not the final efficacy analysis of the study.

Teva sells generics, biosimilars, over-the-counter products and active pharmaceutical ingredients across North America, Europe and its International Markets segment, and it employs about 32,000 people.

No safety concerns were identified in the interim analysis. Teva said it will work with the TOPAS-MSA investigators to make sure study protocols are followed while the study is discontinued.

What Happens to the Emrusolmin Program

Emrusolmin is being developed in Partnership with MODAG. Teva said a comprehensive analysis of the TOPAS-MSA data and available data from the open-label extension study in multiple system atrophy will follow, and it plans to share the findings with the scientific community afterward.

The decision announced today concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program. Teva's head of Research and Development said the company is disappointed but committed to learning from the data and to working out a path forward for the molecule. Multiple system atrophy is a rare neurodegenerative condition with few treatment options, so the readout matters for patients as well as for the pipeline.

Earnings and Analyst View

Teva has a busy week ahead. It reports third-quarter results on Nov. 3, with consensus Earnings per share near $0.73 and Revenue of about $4.24 billion, and it holds an R&D Day on Nov. 11. H.C. Wainwright initiated coverage the same morning with a $52 target and said the setback does not change its thesis, since emrusolmin was not a meaningful part of the company's valuation.

That view helps explain the limited size of the decline. Trailing Earnings Per Share are $2.93, the 52-week range runs from $20.11 to $42.59, and the shares have more than doubled from the low. The next steps to watch are the full TOPAS-MSA analysis, commentary on the broader emrusolmin program during the Earnings Call and R&D Day, and how quickly commercial brands such as Austedo and Uzedy keep growing.